News | August 27, 2021
SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate
The company has to approach the DCGI for approval to commence the trials
The company has to approach the DCGI for approval to commence the trials
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
Subscribe To Our Newsletter & Stay Updated
